Transcriptomic profiling of MCL-1 inhibitor response and resistance in mantle cell lymphoma cell lines and patient PBMCs
RNA-seq (gene expression) · human · 20 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 20 samples: 6 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphomaLeukemia · 2026
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE314603_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1380908. Searching any of these in the dataset finder brings you back here.
Supports a case/control comparison: 7 samples read as cases, 6 as controls.
How we read this: 6 replicated groups read from 20 sample titles; they account for 18 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9405380 HBL-2 parental bulk RNA-seq replicate 1 HBL-2 parental bulk RNA…
- GSM9405381 HBL-2 parental bulk RNA-seq replicate 2 HBL-2 parental bulk RNA…
- GSM9405382 HBL-2 parental bulk RNA-seq replicate 3 HBL-2 parental bulk RNA…
- GSM9405383 HBL-2 treated with S63845 for 72h bulk RNA-seq replicate 1 HBL-2 treated with S638…
- GSM9405384 HBL-2 treated with S63845 for 72h bulk RNA-seq replicate 2 HBL-2 treated with S638…
- GSM9405385 HBL-2 treated with S63845 for 72h bulk RNA-seq replicate 3 HBL-2 treated with S638…
- GSM9405386 HBL-2 MCL-1 inhibitor–resistant bulk RNA-seq replicate 1 HBL-2 MCL-1 inhibitor–r…
- GSM9405387 HBL-2 MCL-1 inhibitor–resistant bulk RNA-seq replicate 2 HBL-2 MCL-1 inhibitor–r…
- GSM9405388 HBL-2 MCL-1 inhibitor–resistant bulk RNA-seq replicate 3 HBL-2 MCL-1 inhibitor–r…
- GSM9405389 Mino parental bulk RNA-seq replicate 1 Mino parental bulk RNA-…
- GSM9405390 Mino parental bulk RNA-seq replicate 2 Mino parental bulk RNA-…
- GSM9405391 Mino parental bulk RNA-seq replicate 3 Mino parental bulk RNA-…
- GSM9405392 Mino treated with S63845 for 72h bulk RNA-seq replicate 1 Mino treated with S6384…
- GSM9405393 Mino treated with S63845 for 72h bulk RNA-seq replicate 2 Mino treated with S6384…
- GSM9405394 Mino treated with S63845 for 72h bulk RNA-seq replicate 3 Mino treated with S6384…
- GSM9405395 Mino MCL-1 inhibitor–resistant bulk RNA-seq replicate 1 Mino MCL-1 inhibitor–re…
- GSM9405396 Mino MCL-1 inhibitor–resistant bulk RNA-seq replicate 2 Mino MCL-1 inhibitor–re…
- GSM9405397 Mino MCL-1 inhibitor–resistant bulk RNA-seq replicate 3 Mino MCL-1 inhibitor–re…
- GSM9405398 PBMC treated with DMSO bulk RNA-seq
- GSM9405399 PBMC treated with S63845 bulk RNA-seq
- GSE286827 4-1BB+ Tregs and inhibitory progenitor exhausted T cells confer resistance to anti-PD-L1 and anti-CTLA-4 combination therapy 87 samples shares resistance, inhibitor
- GSE211434 Diverse immune suppressing cancer communications with myeloid cells prevent T cell activation and recruitment and provide resistance to cell cycle inhibitor therapy 81 samples shares resistance, inhibitor
- GSE289766 Analysis of the mechanism of acquisition of chemotherapy resistance in colorectal cancer cell lines 27 samples shares resistance, lines
- GSE306559 Regulation of temozolomide resistance by m6A mRNA methylation in glioma cell lines 24 samples shares resistance, lines
- GSE303064 Gene expression profile at single cell level of primary and relapse mantle cell lymphoma (MCL) 20 samples shares lymphoma, mantle
- GSE283388 Gene Expression Profiling in Diffuse Large B-Cell Lymphoma (DLBCL) Cell Lines Treated with Selinexor 12 samples shares lymphoma, lines
- GSE300177 Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia 194 samples shares resistance, inhibitor
- GSE324062 RAS pathway activation drives clonal selection and monocytic differentiation in FLT3 and BCL2 inhibitor resistance 61 samples shares resistance, inhibitor
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.